Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + Vyxeos
- Development stage
- Unknown
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
fludarabine + Vyxeos is a combination chemotherapy regimen being investigated by the University of California, San Diego, for the treatment of newly-diagnosed acute myeloid leukemia (AML). The regimen combines fludarabine, a purine analog antimetabolite, with Vyxeos (CPX-351), which is a liposomal formulation containing cytarabine and daunorubicin in a fixed 5:1 molar ratio. Fludarabine acts by inhibiting DNA polymerase and ribonucleotide reductase, thereby interfering with DNA synthesis. Vyxeos is designed to deliver synergistic concentrations of cytarabine (a pyrimidine analog) and daunorubicin (an anthracycline) directly to the bone marrow, where the liposomes are taken up by leukemia cells. This combination aims to enhance the anti-leukemic activity in patients with intermediate or poor-risk AML by combining the targeted delivery of Vyxeos with the DNA-synthesis-inhibiting properties of fludarabine.
- Other names
- fludarabine + CPX-351fludarabine + cytarabine + daunorubicin liposomeUniversity of California Hematologic Malignancies Consortium Protocol 1914
02
Targets
DNADNA polymerase familyDNA-directed primase/polymerase protein (PrimPol)TOP2A (DNA topoisomerase II)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on fludarabine + Vyxeos.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + Vyxeos.